By using logistic regression, we finally evaluated the predictive potential of differential species or metabolites for the major pathologic response of NSCLC neoadjuvant anti‐PD‐1 immunochemotherapy (Figure 4B; Table S10). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.